Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide

[1]  Luca Persani,et al.  GENETICS IN ENDOCRINOLOGY: Genetic diagnosis of endocrine diseases by NGS: novel scenarios and unpredictable results and risks. , 2018, European journal of endocrinology.

[2]  M. Beg,et al.  Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma , 2018, Clinical endocrinology.

[3]  D. Larizza,et al.  A frequent oligogenic involvement in congenital hypothyroidism. , 2017, Human molecular genetics.

[4]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[5]  W. Saeger,et al.  Pasireotide for malignant insulinoma , 2015, Hormones.

[6]  D. Coppola,et al.  Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. , 2014, Endocrine-related cancer.

[7]  S. Mudaliar,et al.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  L. Kvols,et al.  Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. , 2012, Endocrine-related cancer.

[9]  J. Kładny,et al.  Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27 , 2007, Cancer Epidemiology Biomarkers & Prevention.

[10]  P. Rochaix,et al.  Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. , 2005, European journal of endocrinology.

[11]  W. Fisher,et al.  Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. , 2003, The Journal of surgical research.

[12]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[13]  D. Ballard,et al.  Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. , 1991, Mayo Clinic proceedings.

[14]  J. Kros,et al.  Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  L. Kvols,et al.  Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study , 2012 .